Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top 10 Correlated Stocks
QNRX
In the News
Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th
ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.
Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?
QNRX stock is nearly doubling after the company sought permission to cancel an announcement of share sales. The post Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?
Best Penny Stocks To Buy Right Now? 4 To Watch Under $1
Penny stocks under $1 to watch. The post Best Penny Stocks To Buy Right Now?
Penny Stocks To Buy Now? 4 To Watch With Big News
Penny stocks to watch The post Penny Stocks To Buy Now? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Quoin Pharmaceuticals Stock Is Trading Higher
Quoin Pharmaceuticals (NASDAQ: QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigational New Drug application for QRX003. QRX003 is Quoin's investigational product for.
Best Reddit Penny Stocks To Buy Now? 5 Trending Stocks To Watch Today
What are the best penny stocks to buy today? The post Best Reddit Penny Stocks To Buy Now?
Best Penny Stocks to Buy as 2021 Ends? 3 to Watch Right Now
Making a penny stocks watchlist today? Check these three out The post Best Penny Stocks to Buy as 2021 Ends?
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2021-12-31 |
|---|---|---|
| Revenue per share | 0 | |
| Net income per share | -30.71 | |
| Operating cash flow per share | -8.18 | |
| Free cash flow per share | -9.08 | |
| Cash per share | 10.71 | |
| Book value per share | 0.94 | |
| Tangible book value per share | -0.22 | |
| Share holders equity per share | 0.94 | |
| Interest debt per share | 1.95 | |
| Market cap | 10.83M | |
| Enterprise value | 3.35M | |
| P/E ratio | -0.5 | |
| Price to sales ratio | 0 | |
| POCF ratio | -1.89 | |
| PFCF ratio | -1.71 | |
| P/B Ratio | 16.49 | |
| PTB ratio | 16.49 | |
| EV to sales | 0 | |
| Enterprise value over EBITDA | -0.18 | |
| EV to operating cash flow | -0.59 | |
| EV to free cash flow | -0.53 | |
| Earnings yield | -1.98 | |
| Free cash flow yield | -0.59 | |
| Debt to equity | 0 | |
| Debt to assets | 0.93 | |
| Net debt to EBITDA | 0.4 | |
| Current ratio | 0.98 | |
| Interest coverage | -4.44 | |
| Income quality | 0.27 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0 | |
| Intangibles to total assets | 0.09 | |
| Capex to operating cash flow | 0.11 | |
| Capex to revenue | 0 | |
| Capex to depreciation | -6.01 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 25.49 | |
| ROIC | -9.23 | |
| Return on tangible assets | -2.51 | |
| Graham Net | -1.74 | |
| Working capital | -201.57K | |
| Tangible asset value | -151.57K | |
| Net current asset value | -201.57K | |
| Invested capital | 0 | |
| Average receivables | 0 | |
| Average payables | 0 | |
| Average inventory | 0 | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 0 | |
| Days of inventory on hand | 0 | |
| Receivables turnover | 0 | |
| Payables turnover | 0 | |
| Inventory turnover | 0 | |
| ROE | -32.67 | |
| Capex per share | -0.89 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
| Metric | History | 2021-09-30 |
|---|---|---|
| Revenue per share | 0 | |
| Net income per share | -2.02 | |
| Operating cash flow per share | -1.3 | |
| Free cash flow per share | -1.46 | |
| Cash per share | 0.94 | |
| Book value per share | -23.37 | |
| Tangible book value per share | -24.57 | |
| Share holders equity per share | -23.37 | |
| Interest debt per share | 9.29 | |
| Market cap | 12.84M | |
| Enterprise value | 18.4M | |
| P/E ratio | -2.29 | |
| Price to sales ratio | 0 | |
| POCF ratio | -14.15 | |
| PFCF ratio | -12.65 | |
| P/B Ratio | -0.79 | |
| PTB ratio | -0.79 | |
| EV to sales | 0 | |
| Enterprise value over EBITDA | -16.28 | |
| EV to operating cash flow | -20.27 | |
| EV to free cash flow | -18.13 | |
| Earnings yield | -0.11 | |
| Free cash flow yield | -0.08 | |
| Debt to equity | 0 | |
| Debt to assets | 9.82 | |
| Net debt to EBITDA | -4.92 | |
| Current ratio | 0.07 | |
| Interest coverage | -5.25 | |
| Income quality | 0.65 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0 | |
| Intangibles to total assets | 0.45 | |
| Capex to operating cash flow | 0.12 | |
| Capex to revenue | 0 | |
| Capex to depreciation | -4.13 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 32.58 | |
| ROIC | 0.11 | |
| Return on tangible assets | -1.39 | |
| Graham Net | -25.08 | |
| Working capital | -12.61M | |
| Tangible asset value | -17.09M | |
| Net current asset value | -17.14M | |
| Invested capital | -0.38 | |
| Average receivables | 0 | |
| Average payables | 460.8K | |
| Average inventory | 0 | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 0 | |
| Days of inventory on hand | 0 | |
| Receivables turnover | 0 | |
| Payables turnover | 0 | |
| Inventory turnover | 0 | |
| ROE | 0.09 | |
| Capex per share | -0.15 |
Company Profile
- Volume Average 1.2M
- Market Capitalization 4.25M
- Employee 4
- Headquarters Ashburn,VA,US
- IPO Date 2021-10-28
-
Website
https://quoinpharma.com 
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome. The company also offers three other pipeline products in development, which are also targeting rare skin diseases, including epidermolysis bullosa, Netherton Syndrome, and Scleroderma. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia.
